Novo Nordisk's CagriSema Trial Disappoints, Shares Plunge

Novo Nordisk's second late-stage trial data for its obesity drug candidate, CagriSema, failed to meet expectations, leading to significant stock losses. The trial demonstrated weight loss similar to rivals, casting doubt on future sales potentials. Optimistic sales estimates have been revised to $7.25 billion, with regulatory submission planned for early 2026.

Novo Nordisk's share prices took a hit on Monday following the release of uninspiring data from a late-stage trial of its obesity drug candidate, CagriSema. The results, revealed during the REDEFINE 2 trial, failed to position CagriSema as a stronger competitor against Eli Lilly's Mounjaro, a significant player in the weight-loss drugs market.

Novo had hoped that CagriSema would succeed its popular Wegovy as a more potent weight-loss solution. However, the trial's findings showed only a 13.7% reduction in weight over 68 weeks, a figure that falls below the anticipated 15% benchmark necessary to outshine Mounjaro.

The market response was swift and unforgiving, with Novo's shares dropping 8%. Analysts have tempered their forecast for CagriSema's peak sales from an overly optimistic $13 billion to $7.25 billion. Despite the setback, Novo plans to submit the drug for regulatory approval by early 2026, aligning with adjusted timelines.

(With inputs from agencies.)